{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:10:27Z","timestamp":1773259827495,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2990,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.exphem.2013.12.008","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T05:32:11Z","timestamp":1389072731000},"page":"274-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in\u00a0vitro"],"prefix":"10.1016","volume":"42","author":[{"given":"Sung-Hoon","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nu-Ri","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manh-Cuong","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"My-Dung","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Seon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh-Nhan","family":"Nguyen-Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2013.12.008_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2013.12.008_bib2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.008_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.008_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1081\/CNV-120025091","article-title":"The first 1000 dendritic cell vaccinees","volume":"21","author":"Ridgway","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1016\/j.exphem.2013.12.008_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2013.12.008_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","article-title":"Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells","volume":"2","author":"Hsu","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2013.12.008_bib7","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2013.12.008_bib8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.0902539","article-title":"Recent developments in cancer vaccines","volume":"186","author":"Palucka","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib9","doi-asserted-by":"crossref","first-page":"397648","DOI":"10.1155\/2012\/397648","article-title":"Immunotherapy using dendritic cells against multiple myeloma: how to improve?","volume":"2012","author":"Nguyen-Pham","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib10","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.exphem.2013.12.008_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(04)15736-X","article-title":"Multiple myeloma","volume":"363","author":"Sirohi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2013.12.008_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4049\/jimmunol.172.1.464","article-title":"Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer","volume":"172","author":"Nefedova","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib13","first-page":"1270","article-title":"Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase\/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice","volume":"63","author":"Blaskovich","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.12.008_bib14","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.4049\/jimmunol.175.7.4338","article-title":"Activation of dendritic cells via inhibition of Jak2\/STAT3 signaling","volume":"175","author":"Nefedova","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib15","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.008_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.20.100301.064801","article-title":"Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses","volume":"20","author":"Srivastava","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2013.12.008_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.169.3.1151","article-title":"Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR\/CD3 pathway","volume":"169","author":"Matsumoto","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.12.008_bib20","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1038\/sj.onc.1207170","article-title":"Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma","volume":"22","author":"Hideshima","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2013.12.008_bib21","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","article-title":"Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma","volume":"13","author":"Voorhees","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2013.12.008_bib22","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.008_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.12.008_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2013.12.008_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2005.09.010","article-title":"IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells","volume":"23","author":"Kitamura","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2013.12.008_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.leukres.2008.09.006","article-title":"The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma","volume":"33","author":"Yang","year":"2009","journal-title":"Leukemia Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:31:17Z","timestamp":1759566677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0301472X14000046"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2013.12.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in\u00a0vitro","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2013.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}